References
- Anonymous (2013). Clinical guidelines in psoriasis. http://www.vmnvd.gov.lv/lv/420-kliniskas-vadlinijas/klinisko-vadliniju-datu-baze/reistrtas-2013gad/psorizes-klnisks-vadlnijas (accessed 17 November 2014).
- Anonymous (2014). Medical technologies in dermatology confirmed in Latvia http://www.vmnvd.gov.lv/lv/datu-bazes/rstniecb-izmantojamo-medicnisko-tehnoloiju-datu-bze?cat=96#cat96 (accessed 17 November 2014).
- Archier, E., Devaux, S., Castela, E., Gallini, A., Aubin, F., Le Mitre, M., Aractingi, S., Bachelez, H., Cribier, B., Joly, P., Jullien, D., Misery, L., Paul, C., Ortonne, J. P., Richard, M. A. (2012). Efficacy of psoralen UV-A therapy vs. narrowband UV-B therapy inchronic plaque psoriasis: A systematic literature review. JEADV (Journal of the European Academy of Dermatology and Venereology) 26, 11–21.
- Archier, E., Devaux, S., Castela, E., Gallini, A., Aubin, F., Le Maitre, M., Aractingi, S., Bachelez, H., Cribier, B., Joly, P., Jullien, D., Misery, L., Paul, C., Ortonne, J. P., Richard, M. A. (2012). Carcinogenic risks of psoralen UV-A therapy and narrowband UV-B therapy in chronic plaque psoriasis: A systematic literature review. JEADV (Journal of the European Academy of Dermatology and Venereology), 26, 22–31.
- Barbagallo, J., Spann, C. T., Tutrone, W. D., Weinberg, J. M. (2001). Narrowband UVB phototherapy for the treatment of psoriasis: A review and update. Cutis, 68, 345–347
- Bowcock, M., Krueger, J. G. (2005). Getting under the skin: The immunogenetics of psoriasis. Immunology, 5, 699–711.
- Dawe, R. S. (2003). A quantitative review of studies comparing the efficacy of narrow-band ultraviolet B for psoriasis. Brit. J. Dermatol., 149, 669–672.
- Duffin, K. C., Woodcock, J., Krueger, J. G. (2010). Genetic variations associated with psoriasis and psoriatic arthritis found by genome-wide association. Dermatol. Ther., 23, 101–113.
- Hartmane, I. (2004). Psoriāze [Psoriasis]. Rīga. 93 lpp.
- Hartmane, I., Mikazans, I., Derveniece, A., Ivdra, I. (2001) Keratinisation disorders in psoriasis and its treatment with the 1α, 25-dihydroxycholecalciferol, vitamin D3 analoquecalcipotriol. Proc. Latvian Acad. Sci., Section B, 55, 137–144.
- Ivdra, I. (2010). Attribute change of the transforming growth factor beta 1 and epidermal growth factorin blood serum of psoriasis patients and their influence on pathogenetical processes during treatment course. Doctoral Thesis. Rīga Stradiņš University, 194 pp.
- Kostivic, K., Pasic, A. (2004). Phototherapy of psoriasis: Review and update. Acta Dermatovenerol. Croat.,12, 42–50.
- Lapolla, W., Yentzer, B. A., Bagel, J., Halvorson, C. R., Feldman, S. R. (2011). A review of phototherapy protocols for psoriasis treatment. J. Amer. Acad. Dermatol., 64, 936–949.
- Menter, A., Korman, N. J., Elmets, C. A., Feldman, S. R., Gelfand, M., Gordon, K. B., Gottlieb, A., Koo, J. Y. M., Lebwohl, M., Lim, H. W., Van Voorhees, A. S., Beutner, K. R., Bhushan, R. (2010) Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 5. Guidelines of care for the treatment of psoriasis with phototherapy and photochemotherapy. J. Amer. Acad. Dermatol.,62, 114–135.
- Parsed D., Kanwar A., Kumar B. (2006) Phototherapy (UVB and PUVA) in the treatment of psoriasis. JEADV, 20, 175–177.
- Ullrich, S. E., Byrne, S. N. (2012). The immunologic revolution: Photo-immunology. J. Invest. Derm., 132, 896–905.